204376-55-6 Usage
General Description
1-Fmoc-4-piperidone is a chemical compound with the molecular formula C20H23NO3 and a molecular weight of 325.40 g/mol. It is an intermediate in organic synthesis, commonly used in the production of pharmaceuticals, agrochemicals, and other fine chemicals. 1-Fmoc-4-piperidone is a white to off-white crystalline powder, and it is soluble in most organic solvents. It is also used as a building block for the construction of peptide and peptidomimetic libraries. Additionally, it serves as a precursor for the synthesis of various bioactive compounds and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 204376-55-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,3,7 and 6 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 204376-55:
(8*2)+(7*0)+(6*4)+(5*3)+(4*7)+(3*6)+(2*5)+(1*5)=116
116 % 10 = 6
So 204376-55-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H19NO3/c22-14-9-11-21(12-10-14)20(23)24-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,19H,9-13H2
204376-55-6Relevant articles and documents
Mio- and Dio-Fmoc - Two modified Fmoc protecting groups promoting solubility
Wessig, Pablo,Czapla, Sylvia,M?llnitz, Kristian,Schwarz, Jutta
, p. 2235 - 2238 (2006)
Two novel Fmoc-derived protecting groups, Mio-Fmoc and Dio-Fmoc, were developed, which cause dramatically enhanced solubility of the corresponding derivatives in most organic solvents. Furthermore, the suitability of these groups in solid-phase peptide synthesis was highlighted. Georg Thieme Verlag Stuttgart.
ANTI-CD37 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
-
Paragraph 00396-00399, (2021/05/07)
The present disclosure provides anti-CD37 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
-
Paragraph 00389; 00390; 00391; 00392, (2017/08/24)
The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
